Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?

被引：1
|
作者：
Domenech, E. [1 ,2 ]
Canete, F. [1 ]
Manosa, M. [1 ,2 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, IBD Unit, Barcelona, Spain
[2] CIBEREHD, Barcelona, Spain
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2017年 / 46卷 / 11-12期
关键词：
INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; INFLIXIMAB; COMBINATION; ADALIMUMAB; INDUCTION; TRIAL;
D O I：
10.1111/apt.14350
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1113 / 1114
页数：2
相关论文
共 50 条
  • [21] Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges
    Cheli, Stefania
    Savino, Diego
    Penagini, Francesca
    Zuccotti, Gianvincenzo
    Zuin, Giovanna
    Clementi, Emilio
    Cattaneo, Dario
    PHARMACEUTICS, 2023, 15 (07)
  • [22] Is There a Role for Therapeutic Drug Monitoring of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease
    Baert, Filip
    DIGESTIVE DISEASES, 2015, 33 : 70 - 77
  • [23] Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (05): : 673 - 676
  • [24] Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases
    Felice, Carla
    Marzo, Manuela
    Pugliese, Daniela
    Papa, Alfredo
    Rapaccini, Gian Lodovico
    Guidi, Luisa
    Armuzzi, Alessandro
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (08) : 1107 - 1117
  • [25] THE EFFECT OF THERAPEUTIC ANTI-TNF AGENTS ON REVERSE SIGNALING VIA MEMBRANE TNF
    Symons, Antony
    Renshaw, Blair
    Parrelli, Joel
    Sims, John
    ADVANCES IN TNF FAMILY RESEARCH, 2011, 691 : 719 - 719
  • [26] Comparison of causes of drug discontinuation between anti-TNF agents and 'non-anti-TNF biologic agents' in anti-TNF inadequate responder RA patients
    Du Pan, S. Martin
    Neto, D.
    Zufferey, P.
    Ciurea, A.
    Ziswiler, H. R.
    Gabay, C.
    Finckh, A.
    SWISS MEDICAL WEEKLY, 2013, 143 : 5S - 5S
  • [27] Drug survival time on anti-TNF agents: Does prior anti-TNF use influence RA outcomes?
    Kishimoto, M
    Greenberg, J
    Abramson, SB
    Harrington, T
    Olenginski, TP
    Kafka, SP
    Reed, G
    Hinkle, K
    Kremer, J
    Cohen, SB
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S347 - S347
  • [28] Therapeutic Drug Monitoring of the Infliximab (anti-TNF) Level with Bedside Kit in Inflammatory Bowel Disease
    Gur, M. B.
    Bakkaloglu, O. K.
    Eskazan, T.
    Akpinar, A.
    Hatemi, A., I
    Erzin, Y. Z.
    Celik, A. F.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1331 - i1331
  • [29] Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease
    Bernardo, S.
    Fernandes, S.
    Goncalves, A. R.
    Baldaia, C.
    Valente, A.
    Moura Santos, P.
    Correia, L.
    Velosa, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S308 - S309
  • [30] AN INDIAN NATIONAL SURVEY OF THERAPEUTIC DRUG MONITORING WITH ANTI-TNF MEDICATIONS IN INFLAMMATORY BOWEL DISEASE
    Nigam, Gaurav B.
    Patel, Rajan N.
    Jatale, Raj G.
    Makharia, Govind K.
    Ahuja, Vineet
    Desai, Devendra
    Limdi, Jimmy K.
    GASTROENTEROLOGY, 2020, 158 (06) : S246 - S246
12345